AlzforumAlzheimer's & DementiaClinical Trial & PipelineBIDS / NIfTI-1

Open Access Portal

TREM2 Agonistic Antibody Enhances Microglial Clearance of Amyloid-Beta and Restores Synaptic Plasticity

August 2, 2026

Alzforum Therapeutics Tracker Team

Study Design & Technical Specifications

Sample Size / Cohort

Documented in primary study

Subject / Study Model

Human Clinical Cohort

Analytical Modalities

CSF BiomarkersPET ImagingPhase 2 Trials

Executive Research Summary

AI Summary

Preclinical and early Phase 1 data indicate that stimulating the TREM2 receptor activates microglial clearance of amyloid-beta plaques and preserves synaptic plasticity, supporting TREM2 agonism as an immunotherapeutic strategy for Alzheimer's disease.

Primary Abstract & Repository Description

Source: Alzforum

Preclinical and Phase 1 biomarker readouts for novel TREM2-targeted monoclonal antibodies show sustained microglial metabolic reprogramming and enhanced plaque compaction in animal models and early human cohorts.

CNS Open Data Deep Research Brief

Editorial Critique, Methodological Value & Reusability Guide

Structured via CNS Domain Knowledge Engine

1. Scientific Context & Premise

Primary Premise (Alzforum): "Preclinical and Phase 1 biomarker readouts for novel TREM2-targeted monoclonal antibodies show sustained microglial metabolic reprogramming and enhanced plaque compaction in animal models and early human cohorts." Within Alzheimer's Disease (AD), this work examines TREM2, Microglia, Immunotherapy, Therapeutics Tracker, Neuroinflammation in relation to Aβ42/40, p-tau217, p-tau181, GFAP, NfL, and APOE ε4 genotype interactions. Authored by Alzforum Therapeutics Tracker Team.

2. Study Architecture & Findings

Study Architecture: Human Clinical Cohort (primary study cohort) utilizing CSF Biomarkers, PET Imaging, Phase 2 Trials. Key reported conclusion: "Preclinical and Phase 1 biomarker readouts for novel TREM2-targeted monoclonal antibodies show sustained microglial metabolic reprogramming and enhanced plaque compaction in animal models and early human cohorts."

3. Secondary Analysis & Reusability

Secondary Analysis Applications: (1) Cross-referencing CSF Biomarkers, PET Imaging, Phase 2 Trials variables (TREM2, Microglia, Immunotherapy, Therapeutics Tracker, Neuroinflammation) against open repositories in Alzheimer's Disease (AD); (2) Benchmarking feature distributions and effect sizes reported in "TREM2 Agonistic Antibody Enhances Microglial Clearance of Amyloid-Beta and Resto"; (3) Informing cohort stratification and endpoint selection.

4. Methodological Caveats & Governance

Methodological Note: When integrating these CSF Biomarkers, PET Imaging, Phase 2 Trials findings, account for cohort-specific inclusion criteria (primary study cohort), potential site/instrument batch effects, and repository license terms (Open Access Portal).

Related CNS Open Data Research Playbooks & Methodology Guides

Alzheimer's Disease (AD) Open Data Guide: Integrating Neuroimaging (BIDS), Plasma Biomarkers & Multi-Omics

12 min read • Open Playbook

Open Neuroscience Data Governance Guide: CC0, CC-BY, Data Use Agreements (DUA) & Privacy Compliance

10 min read • Open Playbook

Data Access, Reproducibility & Analysis Starter Guide

BIDS (Brain Imaging Data Structure) v1.9+

BIDS / NIfTI-1

Quick Data Access & Structured Export

Open the primary repository directly or download structured metadata (JSON / CSV) in one click.

Open Primary Data (Alzforum)

This neuroimaging resource follows the Brain Imaging Data Structure (BIDS) specification, organizing raw NIfTI volumes (.nii.gz), acquisition parameters (.json sidecars), and participant phenotype tables (participants.tsv) in a deterministic directory hierarchy.

Tags & Modalities

CSF BiomarkersPET ImagingPhase 2 Trials#TREM2#Microglia#Immunotherapy#Therapeutics Tracker#Neuroinflammation

Bibliometrics, Peer-Review Status & Citation Export

Cross-referenced via Semantic Scholar, Europe PMC & bioRxiv

1. Citation Metrics & Context Breakdown

Total Citations

Influential Citations

Citation Context Breakdown

Citation intent breakdown (Supporting vs. Contrasting) is currently accumulating in Semantic Scholar for this record. Researchers reusing this resource should cite the primary DOI/URL using the standardized formats below.

2. Peer-Review Validation & Revision History

Verified Publication / Open Dataset Record

Metadata and license integrity verified against primary repository records.

3. Standardized Academic Citation & BibTeX Export

Selected Format (APA)

Alzforum Therapeutics Tracker Team (2026). TREM2 Agonistic Antibody Enhances Microglial Clearance of Amyloid-Beta and Restores Synaptic Plasticity. Alzforum. https://www.alzforum.org/therapeutics/al002

BibTeX Entry (LaTeX / Reference Managers)

@article{team2026alzf,
  title = {TREM2 Agonistic Antibody Enhances Microglial Clearance of Amyloid-Beta and Restores Synaptic Plasticity},
  author = {Alzforum Therapeutics Tracker Team},
  year = {2026},
  journal = {Alzforum},
  howpublished = {\url{https://www.alzforum.org/therapeutics/al002}},
  doi = {},
  note = {CNS Open Data: alzheimer}
}

Related Alzheimer's & Dementia Research & Datasets

Explore All Datasets

Database / PortalAgora (AMP-AD)

Agora Target Validation: INPP5D (inositol polyphosphate-5-phosphatase D) in Alzheimer’s Disease

This gene is a member of the inositol polyphosphate-5-phosphatase (INPP5) family and encodes a protein with an N-terminal SH2 domain, an inositol phosphatase domain, and two C-terminal protein interaction domains. Expression of this protein is restricted to hematopoietic cells where its movement from the cytosol to the...

11/2/2026Read Analysis

Database / PortalAgora (AMP-AD)

Agora Target Validation: NRN1 (neuritin 1) in Alzheimer’s Disease

This gene encodes a member of the neuritin family, and is expressed in postmitotic-differentiating neurons of the developmental nervous system and neuronal structures associated with plasticity in the adult. The expression of this gene can be induced by neural activity and neurotrophins. The encoded protein contains a ...

11/2/2026Read Analysis

Database / PortalAgora (AMP-AD)

Agora Target Validation: BIN1 (bridging integrator 1) in Alzheimer’s Disease

This gene encodes several isoforms of a nucleocytoplasmic adaptor protein, one of which was initially identified as a MYC-interacting protein with features of a tumor suppressor. Isoforms that are expressed in the central nervous system may be involved in synaptic vesicle endocytosis and may interact with dynamin, syna...

11/2/2026Read Analysis

Database / PortalAgora (AMP-AD)

Agora Target Validation: HTRA1 (HtrA serine peptidase 1) in Alzheimer’s Disease

This gene encodes a member of the trypsin family of serine proteases. This protein is a secreted enzyme that is proposed to regulate the availability of insulin-like growth factors (IGFs) by cleaving IGF-binding proteins. It has also been suggested to be a regulator of cell growth. Variations in the promoter region of ...

11/2/2026Read Analysis

Database / PortalAgora (AMP-AD)

Agora Target Validation: APOE (apolipoprotein E) in Alzheimer’s Disease

The protein encoded by this gene is a major apoprotein of the chylomicron. It binds to a specific liver and peripheral cell receptor, and is essential for the normal catabolism of triglyceride-rich lipoprotein constituents. This gene maps to chromosome 19 in a cluster with the related apolipoprotein C1 and C2 genes. Mu...

11/2/2026Read Analysis

Open DatasetAllen Brain Map / BICCN

Allen Brain Atlas: Multi-plane optical physiology during image change detection

Time series of behavioral variables and neural activity measured with multi-plane in vivo 2-photon imaging in mice performing a visual change detection task where mice were trained with image set A and tested with a novel image set B... Freely accessible open data product maintained by the Allen Institute for Brain Science.

11/2/2026Read Analysis

Active Clinical Trials & Pipeline in Alzheimer's & Dementia

View Clinical Pipeline

ALZFORUM-FALTREM2